L1CAM and neoplasm: CAR-T cells targeting either CD171 (treatment 1) or GD2 (treatment 2) were co-cultured with retinoblastoma cells in a 1:5 effector:target ratio for 3d before examining CD171 and GD2 expression on tumor cells (Fig. 6a).